Table 1

Number of studies, patients and their distributions included in each analysis by the immunohistochemistry technique
IHC ANALYSIS Studies Patients TP FP FN TN
CK-19 [10,14-33] 21 3603 1697 (47.1%) 433 (12.0%) 314 (8.7%) 1159 (32.2%)
GAL-3 [10,14-17,19,21,25-56] 39 5168 2270 (43.9%) 528 (10.2%) 408 (7.9%) 1962 (38.0%)
HBME-1 [10,14-19,21,24-27,29,30,41,51,57-61] 21 3900 1501 (38.5%) 324 (8.3%) 436 (11.2%) 1639 (42.0%)
CK-19 + HBME-1 [14,17] 2 157 84 (53.5%) 2 (1.3%) 14 (8.9%) 57 (36.3%)
GAL-3 + CK-19 [14,17] 2 164 90 (54.9%) 6 (3.7%) 9 (5.5%) 59 (36.0%)
GAL-3 + HBME-1 [14,17,46,51] 4 293 119 (40.6%) 15 (5.1%) 40 (13.7%) 119 (40.6%)
GAL-3 + HBME-1 + CK-19 [14,17,29] 3 231 121 (52.4%) 3 (1.3%) 22 (9.5%) 85 (36.8%)

LEGEND: TP (true-positive), FP (false-positive), FN (false-negative) and TN (true-negative).

de Matos et al.

de Matos et al. Diagnostic Pathology 2012 7:97   doi:10.1186/1746-1596-7-97

Open Data